Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin

A Goulding, Ailsa Goulding, E Gold, Wei Feng, W Feng
Bone and mineral · 1992 · vol. 18(2) , pp. 143–152 · doi:10.1016/0169-6009(92)90854-7 · PMID:1525595 · W2090899781
article OA: closed CC0 ⤵ 2 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

Tamoxifen treatment in rats effectively prevented bone loss caused by estrogen deficiency induced by the LHRH agonist buserelin.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Bone Diseases, Metabolic Bone Resorption Buserelin Estrogens Tamoxifen Animals Body Weight Body Weight Bone Diseases, Metabolic Bone Diseases, Metabolic Bone Resorption Bone Resorption Buserelin Buserelin Calcium Calcium Calcium Disease Models, Animal Drug Interactions Estradiol

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-18T06:15:08.409253+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:44.647872+00:00
unpaywall
last seen: 2026-06-18T06:36:33.011116+00:00
License: CC0 · commercial use OK